Notwithstanding encouraging clinical results, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant opposition from managed care entities. These companies are typically building barriers to reimbursement, like high cost requirements and PA that restrict consumer access. Market belie